| Literature DB >> 28421309 |
A Matussek1,2, C Jernberg3, I-M Einemo4, S Monecke5,6,7, R Ehricht6,7, I Engelmann6,7, S Löfgren8, S Mernelius8.
Abstract
Shiga toxin (Stx)-producing Escherichia coli (STECs) cause non-bloody diarrhea, hemorrhagic colitis, and hemolytic uremic syndrome, and are the primary cause of acute renal failure in children worldwide. This study investigated the correlation of genetic makeup of STEC strains as revealed by DNA microarray to clinical symptoms and the duration of STEC shedding. All STEC isolated (n = 96) from patients <10 years of age in Jönköping County, Sweden from 2003 to 2015 were included. Isolates were characterized by DNA microarray, including almost 280 genes. Clinical data were collected through a questionnaire and by reviewing medical records. Of the 96 virulence genes (including stx) in the microarray, 62 genes were present in at least one isolate. Statistically significant differences in prevalence were observed for 21 genes when comparing patients with bloody diarrhea (BD) and with non-bloody stool (18 of 21 associated with BD). Most genes encode toxins (e.g., stx2 alleles, astA, toxB), adhesion factors (i.e. espB_O157, tir, eae), or secretion factors (e.g., espA, espF, espJ, etpD, nleA, nleB, nleC, tccP). Seven genes were associated with prolonged stx shedding; the presence of three genes (lpfA, senB, and stx1) and the absence of four genes (espB_O157, espF, astA, and intI1). We found STEC genes that might predict severe disease outcome already at diagnosis. This can be used to develop diagnostic tools for risk assessment of disease outcome. Furthermore, genes associated with the duration of stx shedding were detected, enabling a possible better prediction of length of STEC carriage after infection.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28421309 PMCID: PMC5524872 DOI: 10.1007/s10096-017-2950-7
Source DB: PubMed Journal: Eur J Clin Microbiol Infect Dis ISSN: 0934-9723 Impact factor: 3.267
Patient data and clinical symptoms for all cases of STEC infection as well as patients with bloody diarrhea (BD) and with non-bloody stool (NBS)
| All cases | BD | NBS |
| |
|---|---|---|---|---|
| No. (%) | 96 | 17 (18) | 79 (82) | |
| Median age of patients (interquartil range) | 2 (1–5) | 2 (1–4) | 3 (1–6) | 0.3 |
| Median length of carriage, in days (interquartil range) | 24 (14–48) | 22 (11–47) | 24 (14–48) | 0.6 |
| Aquired bacteria abroad (%) | 41 (43) | 5 (29) | 36 (46) | 0.2 |
| Diarrhea (%) | 79 (82) | 17 (100) | 62 (78) | 0.03* |
| Fever (%) | 18 (19) | 8 (47) | 10 (13) | 0.003* |
| HUS (%) | 1 (1) | 1 (6) | 0 (0) | 0.2 |
| Vomiting (%) | 12 (13) | 2 (12) | 10 (13) | 1.0 |
acomparing BD to NBS
*statistically significant difference
Number of isolates with the different stx subtypes
|
| No. | ||
|---|---|---|---|
| Total | BD | NBS | |
|
| 31 | 3 | 28 |
|
| 14 | 1 | 13 |
|
| 8 | 1 | 7 |
|
| 7 | 4 | 3 |
|
| 7 | 5 | 2 |
|
| 6 | 1 | 5 |
|
| 4 | 4 | |
|
| 4 | 4 | |
|
| 3 | 3 | |
|
| 2 | 2 | |
|
| 2 | 2 | |
|
| 2 | 2 | |
|
| 1 | 1 | |
|
| 1 | 1 | |
|
| 1 | 1 | |
|
| 1 | 1 | |
|
| 1 | 1 | |
|
| 1 | 1 | |
asubtype unknown
Fig. 1Distribution of serotypes among STEC causing BD and NBS, ONT O-serotype non-typeable
Prevalence of genes where significant differences were observed in at least one of the comparisons (severity according to stool and age)
| Gene | Severity according to stool | Age (years) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| NBS | BD |
| 0–4 | 5–10 |
| |||||
| pos | prevalence | pos | prevalence | pos | prevalence | pos | prevalence | |||
| eae | 51 | 65% | 16 | 94% | 0.02a | 50 | 74% | 17 | 63% | 0.31 |
| efa1 | 36 | 46% | 7 | 41% | 0.74 | 36 | 53% | 7 | 25% | 0.012a |
| espB_O157 | 11 | 14% | 9 | 53% | 0.0012a | 10 | 15% | 10 | 36% | 0.021a |
| espB_O26 | 34 | 44% | 5 | 33% | 0.44 | 34 | 52% | 5 | 19% | 0.0028a |
| lpfA | 19 | 34% | 0 | 0% | 0.014a | 14 | 30% | 5 | 23% | 0.54 |
| cif | 35 | 44% | 4 | 24% | 0.11 | 34 | 50% | 5 | 18% | 0.0036a |
| espA | 44 | 61% | 13 | 93% | 0.029a | 47 | 72% | 10 | 48% | 0.037a |
| espF | 16 | 20% | 9 | 53% | 0.012a | 13 | 19% | 12 | 43% | 0.016a |
| espF_O103H2 | 35 | 44% | 7 | 41% | 0.81 | 37 | 54% | 5 | 18% | 0.0010a |
| espJ | 51 | 65% | 16 | 94% | 0.016a | 50 | 74% | 17 | 61% | 0.21 |
| etpD | 10 | 13% | 9 | 53% | 0.015a | 10 | 15% | 9 | 32% | 0.056 |
| nleA | 38 | 57% | 11 | 92% | 0.025a | 42 | 69% | 7 | 39% | 0.021a |
| nleB | 50 | 63% | 16 | 94% | 0.013a | 49 | 72% | 17 | 61% | 0.28 |
| nleB O157: | 10 | 15% | 6 | 50% | 0.012a | 13 | 22% | 3 | 14% | 0.45 |
| nleC | 37 | 47% | 15 | 88% | 0.0022a | 38 | 57% | 14 | 50% | 0.55 |
| tccP | 42 | 53% | 15 | 88% | 0.0076a | 41 | 60% | 16 | 57% | 0.76 |
| astA | 38 | 52% | 15 | 88% | 0.0063a | 36 | 57% | 17 | 63% | 0.61 |
| senB | 7 | 9% | 0 | 0% | 0.35 | 3 | 4% | 4 | 14% | 0.19 |
| toxB | 12 | 17% | 9 | 53% | 0.0037a | 13 | 21% | 8 | 31% | 0.33 |
| stx1 | 53 | 68% | 6 | 35% | 0.012a | 42 | 63% | 17 | 61% | 0.86 |
| stx2 | 33 | 42% | 13 | 76% | 0.009a | 30 | 44% | 16 | 57% | 0.25 |
| stx2a | 6 | 9% | 9 | 53% | 0.0001a | 9 | 15% | 6 | 23% | 0.37 |
| stx2c | 9 | 13% | 8 | 50% | 0.0028a | 10 | 17% | 7 | 29% | 0.23 |
| ireA | 7 | 9% | 0 | 0% | 0.34 | 2 | 3% | 5 | 19% | 0.02a |
| iss | 38 | 48% | 3 | 18% | 0.021a | 33 | 49% | 8 | 29% | 0.072 |
| katP | 36 | 46% | 13 | 76% | 0.021a | 36 | 53% | 13 | 46% | 0.056 |
| tir | 50 | 63% | 16 | 94% | 0.013a | 50 | 74% | 16 | 57% | 0.12 |
a significant differences
Prevalence of genes where significant differences were observed in at least one of the comparisons (length of shedding and symptom score)
| Gene | Shedding (weeks) | Total clinical symptom score | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| >3 | <3 |
| 0–4 | 5–10 |
| |||||
| pos | prevalence | pos | prevalence | pos | prevalence | pos | prevalence | |||
| eae | 31 | 72% | 21 | 68% | 0.69 | 58 | 68% | 9 | 90% | 0.27 |
| efa1 | 18 | 42% | 12 | 39% | 0.79 | 42 | 49% | 1 | 10% | 0.02a |
| espB_O157 | 8 | 19% | 10 | 32% | 0.18 | 13 | 15% | 7 | 70% | 0.0005a |
| espB_O26 | 19 | 45% | 8 | 28% | 0.13 | 39 | 47% | 0 | 0% | 0.0091a |
| lpfA | 13 | 38% | 3 | 14% | 0.047a | 18 | 30% | 1 | 11% | 0.43 |
| cif | 19 | 44% | 11 | 35% | 0.45 | 39 | 45% | 0 | 0% | 0.0005a |
| espA | 26 | 68% | 16 | 62% | 0.57 | 51 | 65% | 6 | 86% | 0.42 |
| espF | 11 | 26% | 11 | 35% | 0.36 | 17 | 20% | 8 | 80% | 0.0003a |
| espF_O103H2 | 20 | 47% | 10 | 32% | 0.22 | 41 | 48% | 1 | 10% | 0.039a |
| espJ | 31 | 72% | 21 | 68% | 0.69 | 58 | 67% | 9 | 90% | 0.27 |
| etpD | 8 | 19% | 9 | 30% | 0.26 | 12 | 14% | 7 | 70% | 0.0004a |
| nleA | 22 | 63% | 13 | 57% | 0.63 | 44 | 60% | 5 | 83% | 0.4 |
| nleB | 30 | 70% | 21 | 68% | 0.85 | 57 | 66% | 9 | 90% | 0.16 |
| nleB O157:H7 | 9 | 25% | 6 | 25% | 1.0 | 12 | 16% | 4 | 57% | 0.027a |
| nleC | 22 | 51% | 16 | 53% | 0.86 | 44 | 52% | 8 | 80% | 0.11 |
| tccP | 27 | 63% | 19 | 61% | 0.90 | 48 | 56% | 9 | 90% | 0.045a |
| astA | 23 | 56% | 20 | 65% | 0.47 | 44 | 55% | 9 | 90% | 0.043a |
| senB | 6 | 14% | 0 | 0% | 0.04a | 7 | 8% | 0 | 0% | 1.0 |
| toxB | 11 | 27% | 8 | 30% | 0.80 | 14 | 18% | 7 | 70% | 0.0013a |
| stx1 | 37 | 86% | 15 | 50% | 0.28 | 56 | 66% | 3 | 30% | 0.039a |
| stx2 | 21 | 49% | 16 | 52% | 0.81 | 38 | 44% | 8 | 80% | 0.045a |
| stx2a | 7 | 18% | 5 | 19% | 1.0 | 10 | 13% | 5 | 50% | 0.013a |
| stx2c | 10 | 24% | 7 | 28% | 0.74 | 11 | 15% | 6 | 67% | 0.017a |
| ireA | 2 | 5% | 2 | 6% | 1.0 | 7 | 8% | 0 | 0% | 1.0 |
| iss | 17 | 40% | 15 | 48% | 0.45 | 41 | 48% | 0 | 0% | 0.0044a |
| kalP | 21 | 49% | 17 | 55% | 0.61 | 42 | 49% | 7 | 70% | 0.32 |
| tir | 30 | 70% | 21 | 68% | 0.85 | 58 | 67% | 8 | 80% | 0.72 |
a significant differences
Fig. 2MST based on microarray results of 62 virulence genes for all STEC isolates. eae is present in all strains in groups A and B but in none of the strains in group C. In group A, all strains have an stx2 subtype, and in group B 33% do. In group C, stx1 dominates and 30% harbors stx2b. All strains with serotype O157:H7 are found in group A, and O26:H11 are found in group B. Light grey represents patients with BD and dark grey patients with NBS. The length of the branches is proportional to the distance between the types. The size of the nodes represents the number of isolates included in that type
Fig. 3MST based on the microarray results of 62 virulence genes for all STEC isolates. Dark blue represents patients with a total clinical symptom score of 0, light blue = 1, purple = 2, yellow = 3, orange = 4 and red = 5. The length of the branches is proportional to the distance between the types. The size of the nodes represents the number of isolates included in that type